Tierra Latrice Range Mosher

All Publications

• Intestinal failure in kaposiform hemangioendothelioma successfully resolved with medical therapy and nearly fat-free oral feeding: A novel case report INTESTINAL FAILURE Mosher, T. L., Contijoch, E. J., Bui, J., Teng, J., Jeng, M. R., Namjoshi, S. S. 2026; 9

  View details for DOI 10.1016/j.intf.2025.100347

  View details for Web of Science ID 001779097500011

• Itching for a diagnosis: Dysesthesias as an atypical presentation of Wilson disease in an adolescent—Case report Mosher, T. L., Hicks, J., Mysore, K. R. JPGN Reports. 2026
• A Longitudinal Study of Adolescent Mental Health and Quality of Life as Predictors of College Physical Health, Mental Health, and Gluten-Free Diet Adherence in Celiac Disease. Nutrients Mosher, T. L., Su, L. J., López-Rivera, J. A., Verma, R., Keenan, K., Jericho, H. 2025; 17 (22)

  Abstract

  Background/Objectives: To determine whether adolescent (T1) mental health, quality of life, and adjustment to celiac disease (CeD) are associated with college-age (T2) perceived physical and mental health and gluten-free diet (GFD) adherence. Methods: In 2015, adolescents with CeD (n = 101, T1) completed standardized surveys assessing mental health (CSI-4), quality of life (PedsQL), and adjustment to CeD (CDDUX). Five years later, participants ≥18 years self-reported GFD adherence and physical and mental health perception in college (n = 59, T2). Patients who were current or recent college students that provided complete data at both time points were analyzed (n = 43) using Kendall's tau to test: concurrent associations among T2 perceived physical/mental health and GFD adherence; and prospective associations between T1 measures and T2 perceived outcomes. Results: Higher T1 CSI-4 and PedsQL scores were negatively correlated with T2 perceived physical health (τ = -0.31, p = 0.02 and τ = -0.28, p = 0.04, respectively). There was trending association between T1 PedsQL and T2 mental health perception (τ = -0.23, p = 0.06). T2 physical and mental health perception were positively correlated (τ = 0.41, p = 0.001). No significant associations emerged between T1 measures and T2 GFD adherence, nor between T2 health perception and GFD adherence, although T2 physical health perception positively trended with GFD adherence (p = 0.78). Conclusions: Adolescents with CeD reporting more depressive symptoms or lower quality of life feel less physically and mentally healthy when in college. In college, feeling physically healthy aligns with feeling mentally healthy, although neither clearly predicts GFD adherence. Early mental health screening in adolescents with CeD may support transitions to independent dietary management.

  View details for DOI 10.3390/nu17223568

  View details for PubMedID 41305620

  View details for PubMedCentralID PMC12655353

• Use of glucagon-like-peptide 1 receptor agonist in the treatment of childhood obesity CURRENT OPINION IN PEDIATRICS Kavarian, P. N., Mosher, T. L., Abu El Haija, M. 2024; 36 (5): 542-546

  Abstract

  Pediatric obesity is a growing epidemic. Lifestyle modifications remain central to obesity treatment, however pharmacologic options have gained traction, particularly glucagon-like peptide-1 receptor agonists (GLP-1RA). This review aims to summarize evidence on the use of GLP-1RAs in the management of pediatric obesity, physiological mechanisms of action of GLP-1RAs and their role in appetite regulation and glucose homeostasis and address the challenges and special considerations surrounding GLP-1RA use.Recent studies have highlighted the efficacy of GLP-1RAs, such as exenatide, liraglutide, and semaglutide, in promoting weight loss and improving metabolic parameters in children and adolescents. GLP-1RA's efficacy extends beyond glycemic control to include weight loss mechanisms such as delayed gastric emptying (gastroparesis), and appetite suppression. Semaglutide, the newest GLP-1RA, holds potential for substantial weight loss in adolescents and demonstrates a similar safety and efficacy as seen in adults.GLP-1RAs may offer a promising adjunct therapy for pediatric obesity, particularly in cases where lifestyle interventions alone are insufficient. However, further research is needed to elucidate long-term safety and efficacy outcomes and to address potential disparities in access to care. Overall, this review highlights the relevance and timeliness of incorporating GLP-1RAs into the comprehensive management of pediatric obesity.

  View details for DOI 10.1097/MOP.0000000000001390

  View details for Web of Science ID 001309683200008

  View details for PubMedID 39254757

• Use of glucagon-like-peptide 1 receptor agonist in the treatment of childhood obesity ​​​​​​​​Current Opinion in Pediatrics Kavarian, P. N., Mosher, T. L., Abu El Haija, M. 2024

  View details for DOI 10.1097/MOP.0000000000001379